http://rdf.ncbi.nlm.nih.gov/pubchem/reference/36536957

Outgoing Links

Predicate Object
contentType Journal Article|Research Support, Non-U.S. Gov't|Research Support, U.S. Gov't, Non-P.H.S.|Research Support, N.I.H., Extramural
issn 1558-8238
issueIdentifier 22
publicationName The Journal of clinical investigation
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_d62f51386142d8e7576b9b70134d6e59
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_4c4f4a6c5972ec75e3fd979c7098e660
bibliographicCitation Agarwal S, Fang L, McGowen K, Yin J, Bowman J, Ku AT, Alilin AN, Corey E, Roudier MP, True LD, Dumpit R, Coleman I, Lee JK, Nelson PS, Capaldo BJ, Mariani A, Hoover C, Senatorov IS, Beshiri M, Sowalsky AG, Hurt EM, Kelly K. Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models. J Clin Invest. 2023 Nov 15;133(22). PMID: 37725435; PMCID: PMC10645377.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-6570-2180
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5245e82522f0e05439068e22e82916a7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-3128-3851
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_66ca4267bf3c6f731452a49f4faac2cc
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a4a18533bfc74f98230e306a289893b3
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d08bf03834d16555394b5f04e90c569f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-8722-9646
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-0460-5296
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_be892cb88182eeeef7d488c587c01a40
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b1ed5cc49964d8a3765530c52cdeb148
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-9244-3807
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_20a30fd80069652c2ff9c60f4c3cc0fe
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1f4718d1a13d2934010bb56d99aaa793
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b0f8475651db87c3713430bef6bed6f0
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_50475321c5c822d72d92b079050a2000
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8d4ae84e1d642e86abcd615b2c1a16b0
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-2760-1853
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fadca8bc93277c987fd349022feed0b2
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9599cd4a6cb990cca2f7ea38fb1620ab
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4edceb09892b570093e961ea0b556026
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-8621-9569
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-6471-5502
date 2023-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/PMC10645377
https://doi.org/10.1172/jci162148
https://pubmed.ncbi.nlm.nih.gov/37725435
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/4632
https://portal.issn.org/resource/ISSN/1558-8238
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models
discusses http://id.nlm.nih.gov/mesh/M0579436
http://id.nlm.nih.gov/mesh/M0022149
http://id.nlm.nih.gov/mesh/M0028142
http://id.nlm.nih.gov/mesh/M0015042
http://id.nlm.nih.gov/mesh/M0001483
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D011471Q000188
http://id.nlm.nih.gov/mesh/D000970Q000627
http://id.nlm.nih.gov/mesh/D018796Q000627
http://id.nlm.nih.gov/mesh/D018796Q000494
http://id.nlm.nih.gov/mesh/D011471Q000235
hasSubjectTerm http://id.nlm.nih.gov/mesh/D008297
http://id.nlm.nih.gov/mesh/D045744
http://id.nlm.nih.gov/mesh/D009687
http://id.nlm.nih.gov/mesh/D023041
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D014408Q000235

Total number of triples: 56.